Loading...
SRPT logo
SRPT
Sarepta Therapeutics

Gene Therapy Infusion Delays And Safety Risks Will Spur Improvement

Published
21 Apr 25
Updated
07 May 25
AnalystLowTarget's Fair Value
US$70.00
73.8% undervalued intrinsic discount
11 Jun
US$18.36
Loading
1Y
-85.3%
7D
5.3%

Author's Valuation

US$70

73.8% undervalued intrinsic discount

AnalystLowTarget Fair Value

Narrative
Updates3

Shared on07 May 25
Fair value Decreased 40%

AnalystLowTarget has decreased future PE multiple from 21.8x to 14.5x.

Read more

Shared on30 Apr 25
Fair value Increased 14%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 157%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more